AT1 receptors mediate angiotensin II–induced release of nitric oxide in afferent arterioles  by Patzak, Andreas et al.
Kidney International, Vol. 66 (2004), pp. 1949–1958
AT1 receptors mediate angiotensin II–induced release of nitric
oxide in afferent arterioles
ANDREAS PATZAK, EN Y. LAI, RALF MROWKA, ANDREAS STEEGE, PONTUS B. PERSSON,
and A. ERIK G. PERSSON
Institute of Physiology, Humboldt-University of Berlin, University Hospital Charite´, Berlin, Germany; Department of Medical Cell
Biology, Division of Physiology, Uppsala University, Uppsala, Sweden; and Free University of Berlin, Berlin, Germany
AT1 receptors mediate angiotensin II–induced release of nitric
oxide in afferent arterioles.
Background. Recent studies have indicated that angiotensin
II (Ang II) possibly activates the nitric oxide (NO) system. We
investigated the role of AT receptor subtypes (AT-R) in medi-
ating the Ang II–induced NO release in afferent arterioles (Af)
of mice.
Methods. Isolated Af of mice were perfused, and the isotonic
contraction measured. Further, NO release was determined
using DAF-FM, a fluorescence indicator for NO. Moreover,
we qualitatively assessed the expression of AT-R at the mRNA
level using reverse transcription-polymerase chain reaction
(RT-PCR).
Results. Ang II reduced luminal diameters dose depen-
dently (67.3 ± 6.3% at 10−6 mol/L). Inhibition of AT2-R with
PD123.319 did not change the Ang II contractile response. AT1-
R blockade with ZD7155 inhibited contraction. Stimulation of
AT2-R during AT1-R inhibition with ZD7155, and preconstric-
tion with norepinephrine (NE) had no influence on the diam-
eter. Drug application via the perfusion pipette changed flow
and pressure, and enhanced NO fluorescence by F = 4.0 ±
0.4% (N = 14, background). Luminal application of Ang II
(10−7 mol/L) increased the NO fluorescence by F = 9.9 ±
1.2% (N = 8). AT1-R blockade blunted the increase to back-
ground levels (F to 4.0 ± 0.3%, N = 6, P < 0.05), but AT2-R
blockade did not (8.1 ± 0.9%, N = 9). L-NAME nearly abol-
ished the Ang II effect on the NO fluorescence (F = 1.6 ±
0.5% (N = 8). NE did not increase NO release beyond the
background levels. RT-PCR showed expression of both AT1-R
and AT2-R.
Conclusion. The results indicate an Ang II–induced NO re-
lease in Af of mice, which is mediated by AT1-R. Thus, Ang II
balances its own constrictor action in Af. This control mecha-
nism is very important in view of high renin and angiotensin II
concentration in the juxtaglomerular apparatus.
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Afferent arterioles (Af) are key final elements in the
control of the preglomerular resistance and glomerular
hemodynamics, and contribute largely to the control of
glomerular filtration rate in the kidney. Moreover, the
juxtaglomerular cells in the Af are the main source for
renin production. Since high angiotensin-converting en-
zyme activity has also been found in the kidney, the Af
are confronted with high levels of angiotensin II (Ang II).
To balance the Ang II effect, strong activities of vasodila-
tory systems are assumed. Indeed, it has been demon-
strated from work in isolated perfused Af in rabbits and
mice that the vasoconstrictor effect is counteracted by
locally produced nitric oxide (NO) [1, 2]. In Af of mice,
the basal rate of NO production is low. However, an in-
creased Ang II sensitivity, which has been observed after
pretreatment with the unspecific NO synthase inhibitor
L-NAME, as well as in mice lacking the endothelial NO
synthase (eNOS), indicates an activation of the NO re-
lease by Ang II [2]. Investigations using the microdialysis
technique in the rat renal interstitial fluid also point at an
activation of renal NO systems, suggesting renal vasodila-
tory actions of Ang II, occurring parallel to the effect of
constriction [3–5].
Both types of Ang II receptors (AT1-R and AT2-R)
have been detected at the mRNA and protein level in
the whole kidney, the renal cortex, and in the renal vas-
culature in different species, including humans [6–10].
However, the data are not consistent for the AT2 recep-
tor [11–13]. The individual contribution of both recep-
tor types in mediating the actions of Ang II is unclear.
Extensive experimental evidence, including experiments
in mice, indicates a dominant role of the AT1 receptor
for mediating the constrictor effects on renal resistance
arteries [14–16]. The functional role of AT2 receptors
in vascular control has not been well defined. In vivo
studies suggest that the AT2 receptor causes vasodilation
by stimulating NO, bradykinin, or eicosanoid production
in renal arterioles [17, 18]. Moreover, mice lacking the
AT2 receptor have slightly elevated systolic blood pres-
sures at baseline, and higher pressure sensitivity to Ang II
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compared with that of wild-type controls [19]. This hints
at a role of AT2 receptors for vasodilation.
In contrast, Ang II has been shown to release NO via
the AT1 receptor in endothelial cells and in rings from
the carotid artery [20, 21]. In addition, AT1 receptor in-
hibition blunts Ang II–induced NO release in larger, iso-
lated perfused renal resistant arteries [22]. This suggests
an AT1 receptor–mediated activation of NO systems in
renal resistance vessels.
To investigate the role of AT receptors in the Ang II–
induced NO release in Af, we used different methodic
approaches. We measured the isotonic contraction in
isolated, perfused Af of mice using specific AT1 and
AT2 receptor antagonists. Furthermore, NO release was
quantified using the fluorescent indicator dye DAF-FM
and confocal laser microscopy. The expression of AT1
and AT2 receptors was qualitatively assessed by reverse-
transcription polymerase chain reaction (RT-PCR).
METHODS
Animals
Male mice of the C57BL6 strain were used in the ex-
periments. Body mass was between 20 and 25 g. Animals
were fed with standard mouse chow and allowed free ac-
cess to tap water. All animal procedures conformed with
the guidelines for care and handling of animals estab-
lished by the U.S. Department of Health and Public Ser-
vices and published by the National Institutes of Health.
Dissection and perfusion
Dissection and perfusion procedures have been de-
scribed earlier [2]. The kidneys were immediately re-
moved after killing the animal. They were sliced along
the corticomedullary axis. The Af were dissected at 4◦C in
albumin enriched Dulbecco’s modified Eagle’s medium
(DMEM) (0.1%), The dissection of individual arterioles
was performed under a stereoscopic microscope at mag-
nifications up to 250×, and with help of sharpened forceps
(No. 5; Dumont, Switzerland). The position of Af in the
slice was indicated by the attached glomerulus. Tubuli
were removed with the exception of the region of the
thick ascending limb of Henle’s loop, which touches the
glomerulus. The arterioles were identified by preparation
of the arterial tree, including the interlobular artery. Only
arterioles that were located in the outer part of the renal
cortex (i.e., at the end of the arterial tree) were used.
Time for dissection and following perfusion was limited
to 120 minutes after killing the mouse. The experiment
was terminated if perfusion was not achieved within this
time span.
The arteriole with its glomerulus intact was transferred
into a thermoregulated chamber fixed on the stage at-
tached to a laser confocal microscope (Noran, Middleton,
WI, USA). Arterioles were perfused using a perfusion
system (Vestavia Scientific, Vestavia Hills, AL, USA),
which allowed movement and adjustment of concentric,
holding, and perfusion pipettes. All pipettes were pro-
duced with the help of a self-manufactured apparatus us-
ing custom glass tubes (Drummond Scientific Company,
Broomall, PA, USA). The holding pipette [outer diam-
eter (OD) 2.13 mm, inner diameter (ID) 1.63 mm] had
an aperture of roughly 26 lm at the tip, and a constric-
tion of about 20 lm after customizing. The proximal end
of the arteriole was aspirated into this pipette. The inner
perfusion pipette (OD 1.19 mm, ID 1.02 mm) with a di-
ameter of the tip of 5 lm was advanced into the lumen
of the arteriole. This pipette was connected to a reservoir
containing the perfusion solution and to a manometer.
Af were perfused at 37◦C. The pressure in the pressure
head amounted to 100 mm Hg. To test the autoregulatory
behavior of the Af we measured the response of Af diam-
eter to stepwise increased pressure. The diameter of Af
increased with increasing pressure, but not linearly. The
pressure-diameter curve showed a flat course for most
of the investigated arterioles in a pressure range from
about 100 to 180 mm Hg in the pressure head. We con-
clude from this course that we are at the lower end of the
physiologic pressure range when using a pressure of 100
mm Hg in this perfusion setup. Also, the perfusion rate
of this perfusion setup was measured with the help of a
radioactive-labeled perfusion solution. The rate was cal-
culated to about 50 nL/min using perfusion pipettes with
a diameter of the tip of exactly 5 lm, without attached
arteriole and glomerulus. Since the luminal diameter of
the Af clearly exceeds the inner diameter of the perfusion
pipette, and the resistance of the glomerular capillary net-
work will be low, the measurement is a good estimation
of the real flow through the arteriole during the experi-
ment. The arteriolar perfusion rate fits well to the single
nephron filtration rate, which has been experimentally
determined to 10 nL/min in mice [23].
After starting the perfusion, the solution temperature
was gradually increased, and 20 minutes were allowed
for adaptation. Only arterioles with a good remaining
basal tone were used. Hypoxic or otherwise injured ves-
sels were readily identified by pronounced vasodilatation
and failure to constrict in response to K+ rich solution.
This was used to test the viability of the arterioles at
the beginning of each experiment. The arterioles were
allowed to recover for 10 minutes after the KCl test.
Measurement of isotonic contraction
These experiments were recorded on super video home
system (SVHS) videotapes (video recorder Panasonic
NV-HS830, Matsushita Audio Video GmbH, Lu¨neburg,
Germany). The end magnification results from a Nikon
×60/1.2 water-immersion objective lens and projection
(×1) on a 0.3’’ chip digital camera (VCAM110; Phytec
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Technology Holding AG, Mainz, Germany). Video se-
quences were digitized using a frame grabber card
(pciGrabber-4plus; Phytec Technologie Holding AG).
The vessel diameters were determined using customized
software (Dr. H. Siegmund, Johannes-Mu¨ller-Institute of
Physiology, Humboldt-University of Berlin, Germany).
The equipment allowed a resolution of 0.11 lm of the
vessel structure.
Basal values for the luminal diameter were obtained at
the end of the adaptation period (control values). In all
series, the last 10 seconds of the treatment period were
used for statistical analysis of steady state responses. Only
one Ang II dose-response curve and bolus administra-
tion, respectively, was performed in each of the perfused
arterioles.
NO measurement
To detect the NO production in Af, the NO indicator 4-
amino-5 methylamino-2′,7′-difluorofluorescein diacetate
(DAF-FM DA) was used. DAF-FM diacetate is cell per-
manent and diacetylated by intracellular esterases to
become DAF-FM. It reacts with NO in presence of oxy-
gen forming green-fluorescent triazolofluoresceins [24].
DAF-FM is a further development of DAF-2. The ad-
vantages of DAF-FM are the independence of pH above
5.5, the higher photostability of the adduct of NO and
DAF-FM, and higher sensitivity compared with DAF-
2 [25]. In the presence of NO and oxygen, DAF-FM is
transformed into the triazole fluorescent product. It does
not react with other reactive oxygen species or stable ox-
idized forms of NO. In a recent study, it was shown that
the reaction of diaminofluoresceins is completely inde-
pendent on Ca++ or Mg++ at physiologic concentrations
[26]. Several studies show the usefulness of DAFs for the
determination of NO release in biological tissue [27, 28].
The parallel action of vasoconstrictors like Ang II and
the demand of very minimal movements of the biological
object during confocal microscopy, however, is a major
difficulty. To overcome this problem, Af were pretreated
with cytochalasin D. This substance is a potent inhibitor
of actin filament and contractile microfilaments. It has
been shown that cytochalasin D depresses the isomet-
ric contraction dose dependently in smooth muscle strips
[29]. In our hands, cytochalasin D (10−5 mol/L) applied
for 45 minutes into the bath solution in most cases com-
pletely inhibits the isotonic contraction of isolated, per-
fused arterioles.
The arterioles were loaded from the luminal side with
DAF-FM in a concentration of 10−5 mol/L [solved in
dimethyl sulfoxide (DMSO) with a final concentration of
0.5%]. DAF-FM was mixed with 20% pluronic acid (fi-
nal concentration 0.1%) to facilitate loading. The loading
time amounted to 45 minutes. Simultaneously the arte-
rioles were incubated with cytochalasin D (10−5 mol/L,
solved in DMSO, final concentration 0.5%) from the bath
side. Measurements were carried using a confocal system
(Noran, Middleton, WI, USA), which was setup for DAF-
FM measurements, including software for data collection
and analysis running on a Silicon Graphics workstation
(Mountain View, CA, USA). DAF-FM was excited at
488 nm with an argon-ion laser, while emitted fluores-
cence was recorded at 510 nm. The relative changes of
the DAF-FM fluorescent product concentration were de-
termined calculating the ratio of the fluorescence inten-
sities (I-Irest)/Irest (%). Fluorescence was obtained using
a water immersion objective lens Nikon ×60/1.2. Laser
intensities lower than 30% of the maximum and shutter
operation minimized the photo bleaching. Sample time
for each pixel was 400 ns. The interval between each mea-
surement amounted to 10 seconds.
Protocols
Contraction measurements. Cumulative dose re-
sponse curves for Ang II (10−12 to 10−6 mol/L, each dose
applied for 2 minutes) were obtained in isolated, per-
fused Af. To test a dilatory action of the AT2 receptor,
the dose response curve for Ang II was measured af-
ter pretreatment with PD123.319 (10−5 mol/L), a specific
AT2 antagonist. Further, in a third series, Af were precon-
stricted with norepinephrine (10−5 mol/L), and the Ang
II dose response curve was measured after pretreatment
and with ZD7155 (10−7 mol/L). This substance is a potent
AT1-antagonist, which inhibits Ang II–induced smooth
muscle contraction and intracellular Ca++ increase [30].
To assess the time required for the expected activation
of NO systems, Ang II was applied as a bolus (10−8 mol/L)
with and without pretreatment using L-NAME in a con-
centration of 10−4 mol/L.
Experiments of contractile responses in isolated, per-
fused Af indicated Ang II–induced NO release [2]. To
test the specificity of this Ang II–induced NO release, we
measured the norepinephrine effect on Af with and with-
out L-NAME pretreatment. The duration of exposure of
vessel to norepinephrine was 2 minutes for each dose. For
the analysis of contraction experiments, 5 measurements
of the luminal diameter were averaged during the last
10 seconds of control and treatment periods.
NO imaging. To investigate whether Ang II activates
NO, and which one of the AT receptor subtypes are in-
volved, Ang II (10−7 mol/L), the combination of Ang
II (10−7 mol/L) and PD123.319 (10−5 mol/L), as well as
Ang II (10−7 mol/L) and ZD7155 (10−7 mol/L) were ad-
ministered from the luminal side. All drug combinations
were applied in each arteriole, but in a random order to
exclude systematic errors in drug effects. This protocol
also allows the investigation of a possible desensitization
of the Ang II action on NO release. Ang II alone was
also given from the bath side to test differences in the
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ability to activate the NO systems between both types
of application. There was a washout period of 20 min-
utes separating each application. PD123.319 and ZD7155
were added to the washout solution 10 minutes before
the combined administration together with Ang II. In
view of the blockade of the complete NO production,
Af were pretreated with L-NAME (10−4 mol/L) 20 min-
utes before the Ang II application. Data were sampled
as follows: eight pictures (80 seconds) were obtained as
a control. Another eight pictures belonged to the period
of exchange of the perfusion solution (i.e., the filling of
the perfusion pipette with Ang II as well as Ang II and
AT receptor antagonist). Thereafter, drugs were applied
for a duration of 140 seconds (14 pictures). In the case of
bath application, the exchange time is omitted. In order
to test the specificity of the Ang II effect on NO release,
we applied norepinephrine (10−5 mol/L) from the luminal
side three times in a further series of experiments. Ang II
(10−7 mol/L) was added at the end of each experiment.
For the control and application period five consecu-
tive measurements of the fluorescence intensity during
steady state were averaged for further analysis. The ex-
change of the solution in the perfusion pipette is accom-
panied with low pressure and flow in the Af. To test the
influence of this maneuver on the NO release, the ex-
change was carried out without the application of any
drugs. These “sham” maneuvers were interpolated into
the whole experimental protocol and, in this case, ex-
tended the washout time by about 300 seconds.
Reverse transcription-polymerase chain reaction (RT-
PCR). Arteriolar trees consisting of one interlobu-
lar artery and few afferent arterioles were dissected in
DMEM solution (0.1% BSA) at 4◦C. Total RNA was
isolated from this preparation using RNA Nanoprep-Kit
(Stratagene kat #400753; La Jolla, CA, USA) following
the manufacturer’s recommendations. cDNA was synthe-
sized using reverse transcription (Superscript, Invitrogen
cat #11904–018; Carlsbad, CA,USA) according to manu-
facturer’s protocol. PCR for AT1A (gene bank accession
number: NM-177322) and AT2 receptors (NM-007429)
was performed at 55◦C annealing temperature with 35
cycles from the cDNA template using the following
primers: AT1A fw: CTGAAGCCAGTACCAGCTCT,
AT1A rev: CTGGGGCAGTCATCTTGAAT, AT2 fw:
GCTTACTTCAGCCTGCATTT, AT2 rev: GGACT-
CATTGGTGCCAGTTG. PCR products were visualized
on a 1% agarose gel with ethidium bromide. The AT1A
and the AT2 product have expected sizes of 245bp and
213bp, respectively.
Solutions
Physiologic salt solution (PSS) was used with the fol-
lowing composition: NaCl 115, NaHCO3 25, K2HPO4
2.5, CaCl2 1.3, MgSO4 1.2, and glucose 5.5 (mmol/L).
The K+ solution consisted of 100 mmol/L KCl, whereby
95 mmol/L NaCl were substituted by KCl. DMEM was
used during the dissection. The bicarbonate-buffered so-
lution was equilibrated with 5% CO2 and 95% O2. The
pH was adjusted to 7.4 after addition of bovine serum
albumin (BSA). The concentration of BSA in DMEM
(dissection solution) and in PSS (bath solution) was 0.1%.
The perfusate consisted of PSS with a BSA concentration
of 1%. BSA was obtained from SERVA Electrophore-
sis (Heidelberg, Germany), and DMEM from Sigma-
Aldrich (Munich, Germany).
Drugs
The following drugs were used: Ang II and nore-
pinephrine (Sigma-Aldrich), PD123.319 (Sigma-Aldrich,
Stockholm, Sweden), ZD7155 (Tocris Cookson, Inc.,
Ellisville, MO, USA), NG-Nitro-L-arginine-methylester
(L-NAME, Alexis Biochemicals, Gru¨nberg, Germany),
DAF-FM, and pluronic acid (Molecular Probes, Breda,
The Netherlands).
Statistics
The Brunner test for analysis of longitudinal data was
used to test dose- and time-dependent changes in the arte-
riolar diameter, the differences between two groups, and
to check for differences in the dose dependent changes in
diameter between the groups (SAS, Cary, NC, USA). The
Mann-Whitney U test was applied for the comparison of
fluorescence measurements, and was used for compari-
son of luminal diameters of the different groups in the
steady state during the control situation. Data are pre-
sented as mean ± SEM. The confidence level P was set
to 0.05 for all statistical tests.
RESULTS
Contraction measurements
Ang II applied in concentrations between 10−12 mol/L
and 10−6 mol/L reduced the luminal diameter of Af
dose dependently (N = 8, P < 0.05). Diameters were
diminished to 70.7 ± 5.9% at 10−8 mol/L Ang II and
67.3 ± 6.3% at 10−6 mol/L Ang II (Fig. 1). Pretreat-
ment with PD123.319 (N = 6) neither changed control
diameters significantly nor the Ang II sensitivity of Af
(Fig. 1). To test a putative vasodilatory action of Ang
II via AT2 receptors, Af were preconstricted with nore-
pinephrine (10−5 mol/L), the AT1 receptors were blocked
with ZD7155 (10−7 mol/L pretreatment), and Ang II was
applied in concentrations from 10−12 mol/L to 10−6 mol/L.
Under these conditions, Ang II did not change the lumi-
nal diameter (Fig. 2). The time-dependent changes in the
luminal diameter due to Ang II (10−8 mol/L) bolus appli-
cation with (N = 5) and without L-NAME pretreatment
(N = 5) are shown in Figure 3. Bolus application of Ang
II led to a strong contraction (58.2 ± 3.7%) followed by a
slight increase in the diameter (71.4 ± 9.4%, 4 minutes af-
ter Ang II). This contraction was enhanced by L-NAME
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Fig. 1. Dose-response curve for angiotensin II (Ang II) and Ang II af-
ter treatment with the specific AT2 antagonist PD123.319 (10−5 mol/L).
Arteriolar luminal diameters are given in lm (A) and percent of the
control diameter (B).
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Fig. 2. Lack of effect of AT2 receptor stimulation by cumulative an-
giotensin II concentrations during AT1 receptor blockade (ZD7155
10−7 mol/L) and preconstriction with norepinephrine. Arteriolar lu-
minal diameters are given in lm (A) and percent of control diameter
(B).
pretreatment (27.9 ± 14.3%, P < 0.05); a dilatory phase
was not seen (19.8 ± 9.4% at 4 minutes).
Norepinephrine reduced Af diameters dose depen-
dently (Fig. 4). Diameters were diminished to 63.0 ±
9.3% and 19.3 ± 6.1% (N = 8) at a concentration of
10−6 and 10−5 mol/L. L-NAME pretreatment neither in-
fluenced the diameters during the control situation nor
significantly changed the NE sensitivity of Af (reduction
to 53.6 ± 11.7% and 5.3 ± 5.3% at 10−6 and 10−5 mol/L
NE, N = 6, Fig. 4).
NO imaging
Figure 5 depicts an Af using normal light (Fig. 5A), as
well as images (320 × 240 pixel) of the fluorescence inten-
sity (Fig. 5B and C) using the fluorescent probe DAF-FM
and confocal laser microscopy. The comparison of Figure
5B and C demonstrates an increase of the intensity in the
region of the arteriolar wall after Ang II application. Ang
II (10−7 mol/L) increased the fluorescence intensity (F)
on the average by F = 9.9 ± 1.2% (N = 8) and F = 10.8
± 1.9% (N = 5), when applied from the luminal and bath
side, respectively. PD123.319 pretreatment did not influ-
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Fig. 3. Effect of angiotensin II bolus application on luminal diameter
with and without pretreatment with L-NAME [diameter in lm (A) and
percent of control (B)]. Time courses of the contraction differ signifi-
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Fig. 4. Dose-response curve for norepinephrine (NE) with and with-
out L-NAME pretreatment. L-NAME does not change NE sensitivity
significantly (Brunner test, n.s.). Arteriolar luminal diameters are given
in lm (A) and percent of control diameter (B).
ence the change of the intensity significantly (F = 8.1
± 0.9%, N = 9), but ZD7155 effectively reduced the in-
crease to F = 4.0 ± 0.3% (N = 6, P < 0.05, Fig. 6) in case
of luminal, first application of the drugs. The second and
third administration of Ang II limited the increase of the
fluorescence intensity to F = 5.0 ± 0.9% (N = 8, P <
0.05) and F = 4.7 ± 0.9%, (N = 7, P < 0.05, Fig. 7),
respectively. Similar results were obtained for Ang II af-
ter PD123.319 pretreatment. Values amounted to F =
5.4 ± 0.6% (N = 6, second application, P = 0.06) and
F = 3.7% ± 0.6 (N = 6, third application, P < 0.05).
There were no differences between first, second, and third
application of Ang II when pretreated with ZD7155 (F
= 4.0 ± 0.3%, N = 6, for first application; F = 2.9 ±
0.7%, N = 7, for second application, and F = 3.8 ±
0.4%, N = 11, for third application, Fig. 7).
The exchange procedure induced an increase of the
intensity of F = 4.0 ± 0.4% (N = 14, Fig. 7).
L-NAME pretreatment nearly abolished the Ang II–
induced increase of the fluorescence intensity to F =
1.6 ± 0.5% (N = 8, Fig. 8), which is significantly lower
than the value during the exchange procedure and all
other application of drugs (P < 0.05).
Norepinephrine did not significantly increase the NO
fluorescence beyond the value of the exchange procedure
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Fig. 5. Normal light picture of an isolated, perfused afferent arteri-
ole (A). Red bar indicates the luminal diameter, which was used as a
measure of sensitivity to vasoactive substances. Pseudocolor pictures of
afferent arterioles loaded with DAF-FM (B and C). (C) demonstrates
higher NO fluorescence compared with (B), which is due to three con-
secutive applications of angiotensin II (10−7 mol/L).
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Fig. 6. Changes in NO fluorescence due to angiotensin II application
from the bath side, as well as from the luminal side with and without
treatment with an AT1 receptor antagonist (ZD7155) and an AT2 re-
ceptor antagonist (PD123.319). Afferent arterioles were treated with
cytochalasin D to prevent influence of contraction induced movements
on measurements. ∗Indicates significant differences in fluorescence in-
tensity (P < 0.05).
(5.0 ± 0.6% vs. 4.1 ± 0.7%, Fig. 9). First, second, and third
application of NE did not differ regarding their effect on
NO fluorescence. However, Ang II applied at the end of
the experiment elevated the NO fluorescence by 9.8 ±
0.4%. This value, as well as the NO fluorescence, which
is due to the exchange procedure, are similarly compared
with that in the other series.
Angiotensin II receptor mRNA
A representative gel of AT1A and AT2 receptor
mRNA from the isolated preglomerular arteriolar trees
analyzed by RT-PCR is shown in Figure 10. The analy-
sis consistently detected both AT1A and AT2 receptor
mRNA. The positions correspond to the expected size of
AT1A and AT2 products of 245 bp and 213 bp, respec-
tively.
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Fig. 7. Effect of successive applications of angiotensin II with and with-
out pretreatment with AT receptor antagonists on the change in the
DAF-FM fluorescence. Ang II action on NO fluorescence shows de-
sensitization with significant lower NO fluorescence for the second and
third application. The desensitization effect is masked when using the
AT1 receptor antagonist ZD7155, because the Ang II–induced NO re-
lease is completely inhibited. “Effect of exchange” indicates the in-
crease in fluorescence due to the procedure of exchange of the solution
in the perfusion pipette, which was necessary for drug application from
the luminal side. This value represents a methodically caused basal value
of NO fluorescence. Afferent arterioles were treated with cytochalasin
D. ∗Indicates significant differences in fluorescence intensity (P < 0.05).
DISCUSSION
Recent investigations of isolated perfused Af of mice
revealed only a slight effect of the unspecific blockade of
NO synthases (NOS) with L-NAME on the basal diame-
ters of Af. Nevertheless, L-NAME pretreatment clearly
increased the Ang II sensitivity in these vessels [2]. In
the present study, L-NAME enhanced the contractile re-
sponse to Ang II after bolus application of Ang II. It is
concluded from these studies that Ang II activates NOS
to produce NO, which counteracts the vasoconstrictor ef-
fect of the vasoactive peptide. Contrary to Ang II, the
norepinephrine sensitivity of Af is not significantly in-
fluenced by L-NAME. Therefore, the contraction alone
does not significantly induce NO release. Rather, the ac-
tivation of NO via AT receptors is likely. The lack of
any effect of the AT2 receptor activation or inhibition on
the arteriolar diameter in the present study indicates that
AT1 receptors are involved in the Ang II–induced NO
release in isolated perfused Af.
In our study, Ang II (10−7 mol/L) increased the fluores-
cence intensity by about 10% during luminal application.
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Fig. 8. Pretreatment with L-NAME, which inhibits nitric oxide syn-
thases nonspecifically, nearly abolishes the angiotensin II induced in-
crease of the fluorescence (P < 0.05). Afferent arterioles were treated
with cytochalasin D.
The specific AT2 inhibitor PD123.319 did not change the
increase of the fluorescence due to Ang II significantly.
ZD7155, however, a specific AT1 antagonist, limited the
increase to about 4%. In absence of a complete inhibi-
tion with the AT1 receptor antagonist, we suspect that
the exchange of the solution in the perfusion pipette it-
self could be accompanied by significant changes in NO
release. This exchange procedure is necessary for each
drug application. Our study shows that the exchange pro-
cedure, which goes along with a reduced flow and pres-
sure for about 40 seconds, and following reestablishment
of flow in the arteriole, is able to increase the DAF-FM
fluorescence by about 4% in the Af. Such a flow- and
pressure-dependent release of NO by endothelial cells
has been shown for different arterial beds and endothe-
lial cell cultures [31, 32]. Also, in Af of rabbits, Juncos
et al [33] demonstrated a modulation of the vasocon-
strictor action of Ang II in Af via endothelium-derived
NO and prostaglandins. When the effect of the exchange
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Fig. 9. Changes in fluorescence intensity due to norepinephrine appli-
cation from the luminal side, the exchange procedure, and angiotensin
II application. Afferent arterioles were treated with cytochalasin D.
∗Indicates significant differences in fluorescence intensity (P < 0.05).
procedure is considered, AT1 receptor inhibition totally
blocks the Ang II–induced increase of the DAF-FM flu-
orescence. Furthermore, L-NAME pretreatment abol-
ished not only the specific Ang II effect, but also the
effect of exchange. Only a negligible increase in the fluo-
rescence of about 1.6% could be seen. All together, these
results show that the AT1 receptor mediated the release
of NO from the isolated perfused afferent arteriole in
the mouse. Studies using different indirect methods of
NO measurement applied on endothelial cells, kidneys,
and large vessels also suggested a role of AT1 receptors
in the mediation of Ang II effects on NO release [20–22,
34].
It should be mentioned that different mediators of the
dilatory actions of Ang II are considered to be active
in the kidney. Studies have indicated that AT1 receptors
mediate medullary vasodilation to low doses of Ang II
mainly by the release of prostaglandins, while vasodila-
tion by high doses of Ang II involves also NO- and kinin-
dependent components [35].
Some investigators have suggested that AT2 receptors
are important mediators for the vasodilatory action of
(bp)
300 >
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Fig. 10. Representative gel showing qualitatively AT1A and AT2 re-
ceptor mRNA from isolated preglomerular arteriolar trees analyzed by
RT-PCR.
angiotensin II. In the rat kidney, AT2 receptor stimula-
tion has been associated with the increased production
of bradykinin, NO, and cGMP [36, 37]. Studies in trans-
genic mice selectively overexpressing the AT2 receptor in
vascular smooth muscle cells confirm that AT2 receptors
mediate vasodilation via bradykinin and NO/cGMP sig-
naling [38]. Other recent studies support the idea of a va-
sodilatory effect of AT2 receptors in the control of blood
pressure [39, 40]. Cyclo-oxygenase metabolites might be
the key mediators in the AT2 receptor–mediated blood
pressure–lowering action rather than NO [39]. The sit-
uation in the kidney regarding AT2 receptor function
may be complicated by the more complex renal system
of microcirculation. A study in rabbits suggests that AT2
receptor activation counteracts AT1-mediated vasocon-
striction in the renal cortex, but also counteracts AT1-
mediated vasodilatation in vessels controlling medullary
perfusion [41]. Finally, the possibility that the experimen-
tal model influences the results has been taken into con-
sideration. Therefore, a more pronounced role of AT2
receptors in NO release in renal vessels cannot be ex-
cluded for the in vivo situation.
Little is known regarding the localization of the AT
receptor subtypes in the kidney, especially in the renal
microvasculature. There is evidence from the literature
that AT1 receptor mRNA is expressed throughout the
adult kidney [42, 43]. AT2 receptors, which are highly ex-
pressed in fetal tissue, nearly disappear after birth, with
exception of some tissues, including the kidney [44]. Re-
cent studies have shown AT1A, AT1B, and AT2 receptor
mRNA in pre- and postglomerular vessels of rats [9, 45,
46]. It is concluded from pharmacologic studies in mice
that afferent arteriolar constriction to Ang II is mediated
by AT1A and AT1B receptors, whereas efferent arterio-
lar vasoconstrictor responses are mediated by AT1A re-
ceptors [15]. To our knowledge, there is no investigation
of mRNA in Af of mice so far. Qualitative RT-PCR with
specific primers for AT1A and AT2 demonstrates expres-
sion for both AT receptor types at the mRNA level in Af
in the present study.
In our experiments, the second and third application
of Ang II was significantly less effective in enhancing the
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fluorescence intensity. Pretreatment with the AT2
receptor antagonist PD123.319 did not influence the phe-
nomenon. However, there were no mentionable differ-
ences in the DAF-FM fluorescence comparing the first,
second, and third application of Ang II during AT1 re-
ceptor inhibition using ZD7155. The data show a clear
desensitization of the Ang II–induced enhancement of
fluorescence intensity in the case of unblocked AT1 re-
ceptors. Desensitization is well known for the G-protein
coupled receptors. Although both subtypes of AT recep-
tors belong to the G-protein coupled family, AT1 recep-
tors undergo rapid desensitization and internalization,
AT2 receptors do not [47]. The desensitization of the Ang
II–induced increase of the fluorescence in the present
study supports the idea of an AT1-mediated NO release.
Receptor desensitization that occurs in short time (sec-
onds to minutes) is probably mediated by phosphoryla-
tion, causing uncoupling of activated receptors from G-
proteins, a process that terminates the signal and via re-
ceptor endocytosis, which depletes the plasma membrane
of the receptors. The receptor internalization is part of the
receptor recycling and required for resensitization of the
receptor [48, 49].
CONCLUSION
The present study shows an Ang II–induced activation
of the NO system in Af. This mechanism can prevent the
strong vasoconstrictor influence of Ang II, which occurs
by high renin and angiotensin-converting enzyme activ-
ity in the juxtaglomerular apparatus. AT1 receptors play
a prominent role in mediating the Ang II–induced NO
release.
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